

PARTNERING WITH SERVIER

SERVIER 
moved by you



SERVIER Your strategic partner

moved by you

We are a private, independent pharmaceutical company, governed by a foundation.

Our independence enables a long-term vision and gives us the freedom to make our own strategic decisions.

We are committed to therapeutic progress to service patient needs and driven by a bold ambition to double our revenue by 2030 by reaching €10 billion in sales.

We are present in all the key innovation ecosystems in the world with capabilities ranging from R&D, commercial and manufacturing.

This includes 6 R&D centers, 19 clinical development centers, 13 manufacturing sites and commercial capabilities across the globe.

We are convinced that combining internal and external innovation will enable us to respond to major therapeutic challenges.



AMBITIOUS STRATEGY, STRONG FINANCIAL RESOURCES

Governed by Foundation:
long term &
independent



TRACK RECORD OF SUCCESS

In building our oncology pipeline but now also focused on partnering in rare neurological disorders



A RELIABLE, LONG- TERM PARTNER

Interested in assets from late research through to late clinical



PATIENTS AT THE HEART OF EVERYTHING WE DO

Innovating for the benefit of patients

DISCOVER SERVIER'S AREAS OF FOCUS FOR PARTNERING



Oncology



Therapeutic modalities & technologies



AI & digital technologies applied to R&D



Neurology



Drug discoveries & development technologies



Digital, Data, AI & Beyond-the-Pill

SERVIER VENTURES

Our mission



Contact: **Alexis Vandier**
Global Head of Servier Ventures
alexis.vandier@servier.com

Strategic Focus

Therapeutic focus:



Oncology

precision therapies, antibodies (mabs, ADCs, multi-specifics), small molecules



Neurology

neurodegeneration, rare neurological disorders, ASO

Investment scope:

Development stage:

Pre-IND

Geography:

primarily Europe

Asset types:

High-unmet need, strong differentiation, first-in-class, best in class, technology platforms

Our value proposition



Fund size
€200M,
evergreen



Commitment:
long-term
capital, no fixed
cycles



Investment strategy:
minority equity
investments of **€5 to 10M**,
primarily in **Series A**
financing rounds



A committed partner:
selective access to
Servier expertise &
capabilities



Network:
connection to
Servier venture
syndicates,
incubators and
ecosystem players




Expanding our **ONCOLOGY** pipeline to meet patient needs

We are expanding Servier's pipeline in selected oncology disease areas at all development stages, from research to late clinical.

PARTNERING INTERESTS

Key focus disease areas



1. Others include but not limited to small intestine, anal, appendiceal, Gyn, GU, H&N, thyroid, thymoma.

PARTNERING CONTACTS

Global BD



Anne Dagallier, PhD
Global Head of Licensing Oncology
anne.dagallier@servier.com



Valérie Agrapart, PharmD
Director, Business Development Oncology
valerie.agrapart@servier.com

R&D Search & Evaluation



Irene Blat, PhD
Senior Director, Search & Evaluation, Oncology
irene.blat@servier.com



Alix Scholer-Dahirel, PhD
Director, Business Development Oncology
alix.scholer-dahirel@servier.com



Julie Legrand, PhD
Director, Business Development Oncology
julie.legrand@servier.com



Global BD Coordination
Project Coordination Manager, Oncology
trinh.lam@servier.com



Local BD Asia-Pacific
Director, Business Development
cynthia.wang@servier.com




Building an innovative pipeline in **NEUROLOGY**

Our ambition is to build a new franchise in Rare Neurological Disorders by 2030. Similar to oncology, we will concentrate on hard-to-treat diseases with high medical needs.

PARTNERING INTERESTS

Key focus disease areas



1. FA: Friedreich Ataxia; SCA: Spinocerebellar Ataxia; MSA: Multiple system Atrophy; PSP: Progressive Supranuclear Palsy; HD: Huntington Disease

2. ALS: Amyotrophic Lateral Sclerosis; SMA: Spinal Muscular Atrophy; DMD: Duchene Muscular Dystrophy; FSHD: Fascioscapulohumeral Dystrophy; DM: Myotonic Dystrophy; MG: Myasthenia Gravis

3. DS: Dravet Syndrome; LGS: Lennox-Gastaut Syndrome; JS: Jeavons Syndrome; WS: West Syndrome; DEE: Developmental and Epileptic Encephalopathies

4. ASD: Autism Spectrum Disorders; PMD: Phelan McDermid Syndrome; AG: Angelman Syndrome

5. CMT: Charcot-Marie-Tooth; CIDP: Chronic Inflammatory Demyelinating Polyneuropathy

PARTNERING CONTACTS

Global BD



Marine Beurdeley

**Global Lead
Neurology**

marine.beurdeley@servier.com

R&D Search & Evaluation



Camille Nicoleau, PhD

**Director, Search &
Evaluation, Neurology**

camille.nicoleau@servier.com

Global BD Coordination



Lara-Maria Matar

**Project Coordination
Manager, Neurology**

laramaria.matar@servier.com



David Theron

**Project Director
Neurology**

david.theron@servier.com

Local BD



Asia-Pacific

Cynthia Wang, MBA, MSc

**Director, Business
Development**

cynthia.wang@servier.com



Therapeutic modalities & technologies

PARTNERING INTERESTS

Small Molecules

- Kinase, PPi, Receptor modulators; Molecular Glues, Bifunctional molecules, Small molecule targeting RNA for targeted protein degradation/upregulation
- Targeted delivery: prodrugs/polymer drug conjugates/targeted Lipid Nano Particles, Exosomes, Extracellular Vesicles
- Compound Library

Antibodies

- Novel Formats: Ab Fragments, Single Domain Antibodies, Bi-/ Multi-specifics, optimized Fc domains
- Novel technology platform for Antibody Hard-to-Drug targets
- Synthetic antibody libraries
- ADCs linkage Chemistry/ Conditionally active antibody format

Drug discovery & development technologies

PARTNERING INTERESTS

Phenotypic cell platforms & 3D models

- iPSCs, patient derived models
- Co-culture models
- Organoids, tumoroids (PDAC, CRC, other solid tumors)
- Organ on a chip (liver, brain, kidney)

Protein sciences imaging

- High throughput functional & stability antibody screening
- Antigen specific immuno-oncology assays
- Microfluidic or micro array technology B-cell workflow
- Multi-protein production
- High throughput mass spectrometry based proteomic analysis approach
- Mass spectrometry target

Imaging

- High content imaging (tissues/cells) and analysis
- Multimodal platforms -multiplexing, spatial multiomics strategy, spatial phenotypic quantification
- In vivo visualization of antisense oligonucleotides (ASO) biodistribution
- ASO tolerability assays

Oligonucleotides

- Novel Monomers, Antisense Oligonucleotide (ASO) design technologies, ASO-conjugates and drug delivery systems, targeted saRNA, selective cell ligand targeting for neuronal cell delivery
- Oligo-Manufacturing

PARTNERING CONTACTS

R&D Search & Evaluation



Georges Da Violante

Director, Search & Evaluation, Enabling Technologies

georges.da-violante@servier.com

Global BD Coordination



Delphine Duong

Project Coordination Manager, Research Transactions

delphine.duong@servier.com



Sample optimization

- Universal sample preparation
- Laser Capture Microdissection
- Single cell analysis ATAC (Assay for Transposase Accessible Chromatin)
- High throughput Mass Spectrometry based proteomic analysis approach

Liquid Biopsies

- Circulating tumor DNA (ctDNA) and methylation assay development
- Circulating tumor cells (CTC)
- Exosomes or extracellular vesicle extraction from blood for biomarker identification
- Technology to improve sensitivity
- Computational methods for Next-Generation Sequencing

Flow chemistry

- Multistep synthesis
- Photochemistry, electrochemistry
- Automation of downstream process (quenching, phase separation, distillation)
- Continuous crystallization/drying/milling
- In line analysis
- Continuous manufacturing in pharma



AI & digital technologies applied to R&D

PARTNERING INTERESTS

PARTNERING CONTACTS

Focusing on a patient centered use of AI and digital technologies to:

- Enrich our pipeline by either developing first in class new drugs or by repurposing existing drugs
- Improve treatment effectiveness, reduce adverse effects and enhance patient outcomes
- Accelerate our drug discovery & development processes

Main thematic of our data analytics strategy:

Early research

- Target identification and validation, hit screening and validation, drug design, patient stratification

Late research

- Treatment understanding, DMTA cycle optimization, disease understanding, biomarker identification

R&D Search & Evaluation



Franck Augé, PhD
Director, Search & Evaluation,
AI & Digital Technologies
franck.auge@servier.com

Global BD Coordination



Delphine Duong
Project Coordination Manager,
Research Transactions
delphine.duong@servier.com

Therapeutic modalities:

- Small molecules, antisense oligonucleotides (ASO), antibodies (mAbs, bispecifics, ADCs)

Digital, Data, AI opportunities & Beyond-the-Pill solutions

PARTNERING INTERESTS

PARTNERING CONTACTS

Preferred digital & AI use cases

Initiatives focusing pharma operational efficiency & decision-making

- AI medical, health equity and patient insights management
- Sales forecasts, supply chain, manufacturing & employee optimization

Examples of solutions supporting health care professional (HCPs) activities

- Clinical decision support tools and clinical trials platform optimization
- Remote patient monitoring & dashboards

Examples of beyond-the-pill solutions supporting patients & caregivers

- Solutions supporting adherence (esp. chronic disease) & quality of life
- Patients journey insights and personalization (esp. oncology)
- Solutions offering education and gamification possibilities

Digital Factory Partnering Team



Grégoire Guillet
Chief Business & Value Officer
gregoire.guillet@servier.com



Véronique Frechin
Chief Innovation Officer
veronique.frechin@servier.com



Claire Maze-Sencier
E-Health Business Analyst
claire.mazesencier@servier.com



Marianne Schuler
Scouting Officer
marianne.schuler@servier.com

Preferred modalities

Geographic scope

- Worldwide (or regional)

Deal types

- Co-development, licenses, strategic partnerships & beyond

Preferred maturity stage & technical aspects

- Ready to use solutions
- Previous pharma partnerships
- Medical device (depending on use case)
- Clinical benefits targeted





Partner with us.